Please upgrade your browser.
Preclinical rationale for combination targeted therapy in advanced clear cell renal cell carcinoma (RCC): Abrogation of rapamycin-mediated induction of AKT phosphorylation by perifosine.
Reaffirmed efficacy and safety of the drug as a treatment for advanced kidney cancer.
In patients with advanced renal cell cancer, there was an overall response rate of 35 percent.
"Everolimus should be the standard of care in this setting, pending approval by regulatory authorities."
Data Presented at ASCO Identify Maximum Tolerated Dose and Confirm c-Met Inhibition in Tumors with ARQ 197
ARQ 197 is currently being evaluated in Phase 2 clinical trials in MiT (Microphthalmia Transcription Factor)-driven tumors, which include clear cell sarcoma (CCS), alveolar soft parts sarcoma (ASPS) and translocation-associated renal cell carcinoma (RCC), and in pancreatic cancer.
The results were presented at the annual meeting of the American Society of Clinical Oncology in Chicago.
Tumors disappeared or shrank significantly following treatment. Additionally, several patients with refractory, rapidly-growing melanoma or renal cell carcinoma saw their tumors stop growing for more than six months.
Lancet reported objective response rate of greater than forty percent.
Side Effects of Sunitinib in Kidney Cancer Are 2 to 3 Times More Expensive to Manage Than Those of Avastin Plus Interferon
The Avastin-based therapy patient benefit is comparable in terms of PFS to sunitinib, but the treatment regimens have very different side effect profiles.
"The positive Phase 1 data we presented last month at AACR, coupled with the high investigator and patient interest in this Phase 2 trial, suggests a significant market opportunity for a differentiated VEGF receptor inhibitor. Based on our promising, early data, we believe the unique triple VEGF receptor inhibition and tolerability positions AV-951 as a potential best-in-class anti-angiogenic agent."
|Powered by NeonCRM|